Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study.

Esteban Gándara; Michael J Kovacs; Susan R Kahn; Philip S Wells; David A Anderson; Isabelle Chagnon; Grégoire Le Gal; Susan Solymoss; Mark Crowther; Marc Carrier; Nicole Langlois; Judy Kovacs; Julian Little Ma; Nancy Carson; Tim Ramsay; Marc A Rodger

doi:10.1160/TH13-06-0488

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study.

Esteban Gándara ^{1, 2} Michael J Kovacs ³ Susan R Kahn ^{4, 5} Philip S Wells ^{1, 6} David A Anderson ⁷ Isabelle Chagnon ⁸ Grégoire Le Gal ^{9, 10} Susan Solymoss ⁴ Mark Crowther ¹¹ Marc Carrier ^{1, 2} Nicole Langlois ¹² Judy Kovacs ³ Julian Little Ma ¹³ Nancy Carson ¹⁴ Tim Ramsay ^{1, 2} Marc A Rodger ^{1, 2, *}

* Auteur correspondant

1 Clinical Epidemiology Unit

2 Thrombosis Program

3 LONDON ONTARIO - Med - Department of Medicine

4 Department of Medicine

5 CCECS - Centre for Clinical Epidemiology and Community Studies

6 Thrombosis Program

7 Department of Medicine

8 Department of Medicine

9 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale

10 CIC - Brest - Centre d'Investigation Clinique

11 Department of Medicine

12 IMN - Institut des Matériaux Jean Rouxel

13 OTTAWA - Epidemio - Department of Epidemiology and Community Medicine

14 OTTAWA - Pedia - Department of Pediatrics

Abstract : The role of ABO blood type as a risk factor for recurrent venous thromboembolism (VTE) in patients with a first unprovoked VTE who complete oral anticoagulation therapy is unknown. The aim of this study was to determine if non-OO blood type is a risk factor for recurrent VTE in patients with a first unprovoked VTE who completed 5-7 months of anticoagulant therapy. In an ongoing cohort study of patients with unprovoked VTE who discontinued oral anticoagulation after 5-7 months of therapy, six single nucleotide polymorphisms sites were tested to determine ABO blood type using banked DNA. The main outcome was objectively proven recurrent VTE. Mean follow-up for the cohort was 4.19 years (SD 2.16). During 1,553 patient-years of follow-up, 101 events occurred in 380 non-OO patients (6.5 events per 100 patient years; 95% CI 5.3-7.7) compared to 14 events during 560 patient years of follow-up in 129 OO patients (2.5 per 100 patient years; 95% CI 1.2-3.7), the adjusted hazard ratio was 1.98 (1.2-3.8). In conclusion, non-OO blood type is associated with a statistically significant and clinically relevant increased risk of recurrent VTE following discontinuation of anticoagulant therapy for a first episode of unprovoked VTE.

Type de document :

Article dans une revue

Thrombosis and Haemostasis, Schattauer, 2013, 110 (6), pp.1172-9. 〈10.1160/TH13-06-0488〉

Domaine :

Sciences du Vivant [q-bio]

Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00934053
Contributeur : Ghislaine Calvez <>
Soumis le : mardi 21 janvier 2014 - 15:08:28
Dernière modification le : mercredi 11 juillet 2018 - 18:06:04

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study.

Identifiants

Collections

Citation

Exporter

Métriques

582

Contact

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study.

Identifiants

Collections

Citation

Exporter

Partager

Métriques

582

Contact